Cannabis and Epilepsy Beyond Epidiolex: Whole-Plant Approaches and Emerging Research in 2026

Epidiolex’s FDA approval in 2018 marked a watershed moment for cannabis-based medicine: the first cannabis-derived pharmaceutical approved by the U.S. regulatory system, indicated for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The purified CBD formulation has helped thousands of patients achieve meaningful seizure reduction.

But Epidiolex is not the end of the cannabis-epilepsy story. A growing body of research and considerable patient-reported evidence suggests that whole-plant cannabis extracts, minor cannabinoids, and novel formulations may offer advantages that purified CBD alone does not capture. In 2026, the landscape of cannabis-based epilepsy treatment is considerably broader than a single pharmaceutical product.

Where Epidiolex Excels — and Where It Falls Short

Epidiolex has demonstrated robust efficacy in clinical trials. In pivotal studies, the drug reduced seizure frequency by approximately 40% compared to a 15-20% reduction with placebo in patients with Dravet and Lennox-Gastaut syndromes. For many patients who had exhausted conventional antiepileptic drugs, this represented life-changing improvement.

However, Epidiolex has limitations that have driven interest in alternative cannabis-based approaches:

Incomplete response: A significant percentage of patients do not achieve meaningful seizure reduction with Epidiolex. In clinical trials, approximately 40-50% of patients did not meet the threshold for clinical response (defined as 50% or greater seizure reduction). These non-responders represent a population with significant unmet need.

Side effects: Epidiolex carries notable side effects including somnolence, decreased appetite, diarrhea, and — importantly — elevated liver enzymes that require monitoring. These side effects lead some patients to discontinue treatment.

Cost: At approximately $32,000 per year before insurance, Epidiolex is prohibitively expensive for many patients, particularly those without robust prescription drug coverage. Generic CBD products are vastly cheaper but lack the standardization and quality assurance of the pharmaceutical product.

Narrow cannabinoid profile: As a purified CBD formulation, Epidiolex delivers a single cannabinoid. This raises the question of whether the therapeutic benefits could be enhanced by the presence of additional cannabis compounds.

The Case for Whole-Plant Extracts

The most compelling argument for whole-plant cannabis extracts in epilepsy comes from a comparison study that has become foundational in this discussion. A 2018 meta-analysis published in Epilepsy & Behavior compared outcomes in patients using CBD-rich whole-plant extracts versus purified CBD products. The findings were striking:

Patients using CBD-rich whole-plant extracts reported a 71% seizure improvement rate compared to 46% for purified CBD products. Whole-plant extract users also required lower average CBD doses (estimated 6mg/kg/day versus 25.3mg/kg/day for purified CBD) and reported fewer adverse effects.

While this meta-analysis had limitations — it compared across studies rather than within a single controlled trial — the magnitude of the difference prompted serious scientific interest in why whole-plant extracts might outperform purified CBD.

Several hypotheses have been proposed:

Entourage effect: The presence of minor cannabinoids (CBDV, CBG, CBC, THCA) and terpenes may enhance CBD’s antiepileptic activity through synergistic interactions at multiple neurological targets. This concept aligns with broader research on the entourage effect in cannabis therapeutics.

Trace THC: Whole-plant CBD extracts typically contain small amounts of THC (below 0.3% in hemp-derived products, variable in medical cannabis products). Even sub-psychoactive THC levels may contribute to seizure control through mechanisms distinct from CBD’s activity.

Terpene contributions: Specific terpenes found in cannabis — particularly linalool and beta-caryophyllene — have demonstrated independent anticonvulsant properties in preclinical studies.

Minor Cannabinoids Under Investigation

Research attention has expanded beyond CBD and THC to several minor cannabinoids with anticonvulsant potential:

CBDV (Cannabidivarin): Structurally similar to CBD, CBDV has demonstrated anticonvulsant effects in multiple animal seizure models. GW Pharmaceuticals (now Jazz Pharmaceuticals) advanced CBDV into clinical trials for epilepsy, and early results suggest activity that may complement CBD’s effects. CBDV appears to act through TRPV1 channel desensitization and may be particularly effective in seizure types that respond less well to CBD alone.

CBG (Cannabigerol): Preclinical research published in 2024 demonstrated that CBG reduced seizure frequency and duration in a Dravet syndrome mouse model. CBG’s mechanism appears to involve GABAergic modulation — enhancing the brain’s primary inhibitory neurotransmitter system. This is mechanistically distinct from CBD’s primary pathways, suggesting potential for complementary effects.

THCA (Tetrahydrocannabinolic Acid): The non-psychoactive precursor to THC has shown anticonvulsant properties in preliminary research. Several medical cannabis programs have noted that patients using raw cannabis preparations (which contain THCA rather than THC) report seizure reduction, though controlled clinical data is limited.

CBC (Cannabichromene): Less studied than other minor cannabinoids for epilepsy, CBC has shown antinociceptive and anti-inflammatory properties that may indirectly support neurological health. Its interaction with the endocannabinoid system through TRPA1 channels is being investigated for potential anticonvulsant relevance.

Emerging Clinical Research

Several clinical studies are advancing the evidence base beyond Epidiolex:

The Australian Observational Study: A large prospective observational study following over 500 epilepsy patients using medical cannabis products (various formulations including whole-plant extracts) has been reporting data since 2023. Interim results show seizure reduction rates comparable to or exceeding Epidiolex clinical trials, with particular efficacy noted in patients using full-spectrum products containing measured ratios of CBD, THC, and minor cannabinoids.

The Israeli Pediatric Cohort: Israel’s advanced medical cannabis program has enabled longitudinal tracking of pediatric epilepsy patients using various cannabis formulations. A 2025 publication reported that children using standardized whole-plant extracts with CBD:THC ratios of 20:1 achieved a 56% average seizure reduction over 12 months, with 23% achieving seizure freedom — a notably higher seizure-freedom rate than reported in Epidiolex trials.

Jazz Pharmaceuticals Pipeline: The company that acquired GW Pharmaceuticals continues to develop cannabis-derived pharmaceuticals for epilepsy, including formulations that combine CBD with other cannabinoids. Their research pipeline includes a CBD/CBDV combination product that has entered phase II trials for treatment-resistant focal epilepsy.

Academic Investigator-Initiated Trials: University-based researchers in the U.S., Canada, and Europe are conducting smaller trials examining specific cannabinoid combinations, novel delivery methods (intranasal CBD for seizure clusters), and personalized approaches that match cannabinoid ratios to seizure type and patient genetics.

Practical Considerations for Patients

For patients and caregivers navigating the landscape beyond Epidiolex, several practical considerations apply:

Medical supervision is essential: Epilepsy is a serious condition where treatment decisions have significant consequences. Any exploration of cannabis-based approaches should occur under the guidance of a neurologist experienced with cannabis medicine.

Product quality varies enormously: Unlike Epidiolex, which is manufactured to pharmaceutical standards, medical cannabis and CBD products have highly variable quality. Third-party testing, certificate of analysis review, and sourcing from reputable producers are critical.

Drug interactions require monitoring: CBD and other cannabinoids interact with multiple antiepileptic drugs through cytochrome P450 enzyme inhibition. Clobazam, valproate, and other common epilepsy medications can have their blood levels altered by cannabis co-administration, requiring dose adjustments and monitoring.

Dosing is empirical: Without the standardized dosing guidelines available for Epidiolex, whole-plant cannabis dosing for epilepsy is largely empirical — starting low, increasing gradually, and monitoring seizure frequency and side effects. The principles of cannabis microdosing provide relevant context for dose titration approaches.

The Regulatory Landscape

The regulatory environment for cannabis-based epilepsy treatments reflects the broader tension between pharmaceutical development and medical cannabis access:

FDA-approved Epidiolex provides a clear, regulated pathway but is expensive and limited to purified CBD. Medical cannabis programs in most states allow access to a broader range of cannabis products for epilepsy, but with less standardization and limited clinical guidance.

The DEA’s rescheduling review could significantly impact this landscape. Moving cannabis to Schedule III would facilitate research and potentially enable new cannabis-derived pharmaceuticals to reach market more efficiently. Meanwhile, state medical cannabis programs continue to evolve their regulations around epilepsy-specific product formulations and physician oversight requirements.

Looking Ahead

The trajectory of cannabis-based epilepsy treatment points toward increasingly sophisticated, multi-cannabinoid approaches that move beyond the single-molecule pharmaceutical model. The evidence base is building, clinical trials are expanding, and patient outcomes data from medical cannabis programs worldwide is providing real-world validation.

For the roughly one-third of epilepsy patients whose seizures remain uncontrolled by conventional medications, the cannabis research pipeline offers genuine hope — not as a miracle cure, but as a growing toolkit of compounds and formulations that may succeed where single-target pharmaceuticals have failed. The science is catching up to what many patient families have known for years: cannabis has a role in epilepsy treatment, and that role extends well beyond a single purified compound.